Role of mesenchymal stem cells in delivering Newcastle disease virus to glioma cells and glioma stem cells and enhancing the oncolytic effect of the virus by secreting TRAIL.
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3100)Outcome of an advanced anaplastic astrocytoma patient treated with Newcastle disease viral (NDV) oncolytic therapy.
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e13029)The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling
/in Hypernephroma, International Publications, Newcastle Disease Virus /von 2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-54Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2013-01-23 / J. Virol. 2013 Apr;87(7):3792-800Oncolytic virus therapy for cancer: the first wave of translational clinical trials
/in International Publications, Newcastle Disease Virus /von 2013-01-10 / Transl Res 2013 Apr;161(4):355-64Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2012-09-10 / JOP 2012 Sep;13(5):502-13The use of oncolytic viruses to overcome lung cancer drug resistance
/in International Publications, Newcastle Disease Virus /von 2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35Newcastle disease virus: a promising agent for tumour immunotherapy
/in International Publications, Newcastle Disease Virus /von 2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de